As of the latest Form 4 filed Jul 7, 2026.
What Uniqure NV insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 57 most recent filings for QURE.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | 2026-07-02 | Kapusta Matthew C CEO, Managing Director | SSale | −7.60K | $45.89 | $349K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Kapusta Matthew C, CEO, Managing Director | SSale | −4.28K | $45.43 | $195K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Kapusta Matthew C, CEO, Managing Director | SSale | −9.20K | $44.43 | $409K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Kapusta Matthew C, CEO, Managing Director | MExercise | +21.1K | $19.39 | $409K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Abi-Saab Walid Chief Medical Officer | SSale | −20.0K | $46.40 | $928K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Abi-Saab Walid, Chief Medical Officer | SSale | −10.0K | $46.46 | $465K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Abi-Saab Walid, Chief Medical Officer | MExercise | +10.0K | $5.59 | $55.9K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Kaye Jack Director | SSale | −17.1K | $46.43 | $792K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Kaye Jack, Director | MExercise | +17.1K | $20.18 | $344K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Kaye Jack, Director | SSale | −4.11K | $46.49 | $191K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Kaye Jack, Director | MExercise | +4.11K | $37.00 | $152K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Abi-Saab Walid Chief Medical Officer | SSale | −1.43K | $46.86 | $67.2K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Kapusta Matthew C CEO, Managing Director | SSale | −28.7K | $50.02 | $1.44M | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-25 | Kapusta Matthew C, CEO, Managing Director | MExercise | +28.7K | $31.71 | $911K | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | Kapusta Matthew C, CEO, Managing Director | SSale | −6.70K | $50.00 | $335K | Yes (planned) | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | Kapusta Matthew C, CEO, Managing Director | MExercise | +4.13K | $31.71 | $131K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-18 | Kapusta Matthew C CEO, Managing Director | SSale | −37.0K | $50.00 | $1.85M | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-18 | Kapusta Matthew C, CEO, Managing Director | SSale | −4.66K | $50.00 | $233K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-18 | Kapusta Matthew C, CEO, Managing Director | MExercise | +4.66K | $31.71 | $148K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Kapusta Matthew C, CEO, Managing Director | SSale | −11.6K | $48.65 | $564K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Kapusta Matthew C, CEO, Managing Director | SSale | −33.3K | $45.01 | $1.50M | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Kapusta Matthew C, CEO, Managing Director | SSale | −56.9K | $43.43 | $2.47M | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Kapusta Matthew C, CEO, Managing Director | SSale | −32.6K | $45.02 | $1.47M | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Kapusta Matthew C, CEO, Managing Director | SSale | −6.02K | $43.70 | $263K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Kapusta Matthew C, CEO, Managing Director | SSale | −24.0K | $42.61 | $1.02M | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Kapusta Matthew C, CEO, Managing Director | MExercise | +62.6K | $19.39 | $1.21M | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Balachandran Madhavan Director | SSale | −1.69K | $42.60 | $72.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Balachandran Madhavan, Director | SSale | −4.70K | $43.66 | $205K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Balachandran Madhavan, Director | SSale | −5.29K | $47.08 | $249K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Balachandran Madhavan, Director | MExercise | +6.39K | $19.39 | $124K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Balachandran Madhavan, Director | MExercise | +5.29K | $31.71 | $168K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Kaye Jack Director | SSale | −5.29K | $42.57 | $225K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Kaye Jack, Director | MExercise | +5.29K | $31.71 | $168K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Balachandran Madhavan Director | SSale | −10.0K | $27.85 | $279K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Balachandran Madhavan, Director | MExercise | +10.0K | $8.49 | $84.9K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Potts Jeannette Chief Legal Officer | SSale | −5.24K | $27.67 | $145K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Meek David D. Director | SSale | −1.99K | $27.06 | $53.9K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Gut Robert Director | SSale | −2.73K | $27.06 | $73.8K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | O'Keefe Kylie Chief Customer & Strat Officer | SSale | −15.9K | $27.06 | $431K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Springhorn Jeremy P. Director | SSale | −1.99K | $27.06 | $53.9K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | POST LEONARD E Director | SSale | −1.99K | $27.06 | $53.9K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Kaye Jack Director | SSale | −1.99K | $27.06 | $53.9K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Jacques Rachelle Suzanne Director | SSale | −1.99K | $27.06 | $53.9K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Balachandran Madhavan Director | SSale | −1.99K | $27.06 | $53.9K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Meek David D. Director | AAward | +7.55K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Gut Robert Director | AAward | +7.55K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Gut Robert, Director | SSale | −1.78K | $26.05 | $46.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Gut Robert, Director | SSale | −3.13K | $26.03 | $81.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Gut Robert, Director | SSale | −2.65K | $26.07 | $69.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Gut Robert, Director | MExercise | +2.65K | $16.04 | $42.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Springhorn Jeremy P. Director | AAward | +7.55K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | POST LEONARD E Director | AAward | +7.55K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Kaye Jack Director | AAward | +7.55K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Jacques Rachelle Suzanne Director | AAward | +7.55K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Balachandran Madhavan Director | AAward | +7.55K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Kaye Jack Director | SSale | −2.65K | $30.01 | $79.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | Kaye Jack, Director | MExercise | +2.65K | $16.04 | $42.4K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also QURE’s full analysis or the market-wide insider trading feed. The tabs above jump to QURE’s other SEC data.
Source: SEC Form 4 filings for QURE, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.